Synopsys, Inc. (SNPS) Stock Price Today
Aura AI Summary
Key Stats
- $77.74BMarket Cap
- -Volume
- TechnologySector
- $625.8052W High
- $372.3352W Low
- -Typical Hold Time
- $86.09BEnterprise Value
- -Div Yield
- -Trading Activity
Track Synopsys, Inc. (SNPS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Synopsys, Inc. has traded between a low of $372.33 and a high of $625.8, highlighting its annual price range. Buy and sell Synopsys, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Most Recent News
Gold's biggest headwind from rising real yields may be over, setting stage for recovery.
Gold has faced strong pressure in 2026 due to rising real interest rates increasing the opportunity cost of holding non-yielding gold. However, analysts like BCA Research suggest that real yields may have peaked, meaning the worst impact on gold pric...
OpenAI halts work on Astra model after it shows risky cybersecurity capabilities.
OpenAI has paused development on its upcoming AI model Astra after internal tests revealed it could independently execute cyberattacks on secure systems, triggering the company's cybersecurity safeguards. This move follows a recent incident where ano...
Medline stock drops over 19% after FDA cites major manufacturing violations and lowers earnings forecast.
Medline Inc. faced significant FDA violations related to manufacturing quality, including failure to investigate contamination and cleaning issues, leading to a stock drop of over 7% initially. The stock further fell by more than 12% following disapp...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.